Prior to these recent clinical trial results, I was optimistic that MariTide could make Amgen an underrated stock to own. Patients having just a monthly injection which might yield similar weight ...

Sales of GLP-1 drugs Mounjaro and Zepbound disappointed investors.Shelby Knowles/Bloomberg News Eli Lilly had a bad quarter, with sales of GLP-1 drugs Mounjaro and Zepbound missing analyst estimates.

To be clear, orforglipron didn't flop in its late-stage study. The company said that all three doses of the experimental drug met the primary end point of the trial as well as all key secondary end ...

Eli Lilly on Tuesday said its daily obesity pill succeeded in another late-stage trial, helping patients with obesity and Type 2 diabetes lose weight and lower their blood sugar levels. The company ...

Lilly says weight-loss pill meets three out of four criteria for FDA commissioner voucher International Mounjaro sales exceed estimates by nearly $1 billion Third-quarter beat reinforces Lilly lead in ...

Eli Lilly (LLY) announced that its gene editing candidate VERVE-102, added from its $1.3B acquisition of Verve Therapeutics last year, caused up to a 62% average decline in low-density lipoprotein ...